Bayer and Onyx's cancer treatment Nexavar has failed to show benefit in preventing the return of liver cancer after surgery. The drug is already approved in patients with hepatocellular carcinoma ...

Bayer’s liver cancer treatment Nexavar has been judged not to be value for money by England’s cost effectiveness watchdog NICE. The drug is currently available for this indication via the ...

SBRT combined with Nexavar improved median OS to 15.8 months versus 12.3 months with Nexavar alone in patients with advanced HCC. Median PFS increased from 5.5 months with Nexavar alone to 9.2 months ...